Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 clinical trials
Also written IBI363.
Its developmentBy Innovent Biologics, step by step10 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 9
Innovent Biologics (Suzhou) Co. Ltd. (10) · Shanghai Pulmonary Hospital, Shanghai, China (2) · The First Affiliated Hospital of Zhengzhou University (1) · Ruijin Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Zhejiang Cancer Hospital (1) · Wuhan Union Hospital, China (1) · Xiangdong Cheng (1)
Often tested with
Tested in the same studies.
Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · MT027 (1) · QH101 (1) · META10 (1) · TAEST1901 (1) · TCN 201 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363.
- Nov 2026IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerPhase 2 · Innovent Biologics (Suzhou) Co. Ltd.
- Dec 2026The Efficacy and Safety of IBI363 in Solid TumorsPhase 1/2 · Hunan Province Tumor Hospital
- Dec 2026A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyPhase 2 · Innovent Biologics (Suzhou) Co. Ltd.
- Dec 2026Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or LymphomaPhase 1 · Innovent Biologics (Suzhou) Co. Ltd.
- Dec 2026IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung CancerPhase 2 · Innovent Biologics (Suzhou) Co. Ltd.
Studies
Open first, then newest update. How each study uses Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07722494Written as IBI363 + bevacizumabHow we know
- A Study of IBI363 in Subjects With Advanced MelanomaRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06081920Written as IBI363How we know
- IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07122687Written as IBI363How we know
- IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung CancerRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07408635Written as IBI363 + ChemotherapyHow we know
- IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung CancerNot yet recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07402070Written as IBI363How we know
- IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric CancerNot yet recruitingPhase 1/2The First Affiliated Hospital of Zhengzhou UniversityNCT07361991Written as IBI363How we know
- Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic CancerNot yet recruitingPhase 1/2Ruijin HospitalNCT07342725Written as IBI363 + chemotherapyHow we know
- Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric CancerRecruitingPhase 2Zhejiang Cancer HospitalNCT07325630Written as IBI363 + chemotherapyHow we know
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07307053Written as IBI363How we know
- A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsNot yet recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07124793Written as IBI363+IBI305How we know
- A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal CancerRecruitingPhase 1Wuhan Union Hospital, ChinaNCT06717880Written as IBI363 combined with BevacizumabHow we know
- A Study of IBI363 in Subjects with Advanced Solid MalignanciesRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06281678Written as IBI363How we know
- Study of IBI363 in Patients with Advanced First-line Gastric CancerRecruitingPhase 1Xiangdong ChengNCT06610799Written as IBI363How we know
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06620822Written as IBI363How we know
- A Study of IBI363 in Subjects With Advanced MalignanciesRecruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT06468098Written as IBI363 + chemotherapyHow we know
- The Efficacy and Safety of IBI363 in Solid TumorsRecruitingPhase 1/2Hunan Province Tumor HospitalNCT06081907Written as IBI363How we know
- A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyActive, not recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06797297Written as IBI363How we know
- Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or LymphomaActive, not recruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05460767Written as IBI363How we know
- A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or LymphomasActive, not recruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05290597Written as IBI363How we know